Success Metrics

Clinical Success Rate
89.1%

Based on 814 completed trials

Completion Rate
89%(814/914)
Active Trials
108(8%)
Results Posted
43%(354 trials)
Terminated
100(8%)

Phase Distribution

Ph early_phase_1
37
3%
Ph phase_1
211
16%
Ph phase_2
294
23%
Ph phase_4
299
23%
Ph phase_3
275
21%
Ph not_applicable
142
11%

Phase Distribution

248

Early Stage

294

Mid Stage

574

Late Stage

Phase Distribution1258 total trials
Early Phase 1First-in-human
37(2.9%)
Phase 1Safety & dosage
211(16.8%)
Phase 2Efficacy & side effects
294(23.4%)
Phase 3Large-scale testing
275(21.9%)
Phase 4Post-market surveillance
299(23.8%)
N/ANon-phased studies
142(11.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.0%

814 of 958 finished

Non-Completion Rate

15.0%

144 ended early

Currently Active

108

trials recruiting

Total Trials

1,289

all time

Status Distribution
Active(147)
Completed(814)
Terminated(144)
Other(184)

Detailed Status

Completed814
unknown182
Terminated100
Recruiting82
Withdrawn44
Not yet recruiting33

Development Timeline

Analytics

Development Status

Total Trials
1289
Active
108
Success Rate
89.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 137 (2.9%)
Phase 1211 (16.8%)
Phase 2294 (23.4%)
Phase 3275 (21.9%)
Phase 4299 (23.8%)
N/A142 (11.3%)

Trials by Status

terminated1008%
withdrawn443%
not_yet_recruiting333%
active_not_recruiting262%
recruiting826%
suspended20%
unknown18214%
completed81463%
enrolling_by_invitation60%

Recent Activity

Clinical Trials (1,289)

Showing 20 of 1,289 trialsScroll for more
NCT01762046Phase 1

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Completed
NCT07570082Phase 1

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

Recruiting
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT07446400Phase 1

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Recruiting
NCT07222098Phase 1

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

Completed
NCT05093959Phase 2

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

Completed
NCT07567781Phase 1

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

Recruiting
NCT06975111Phase 2

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Recruiting
NCT04742751Phase 2

An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer

Active Not Recruiting
NCT07275359Phase 1

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

Not Yet Recruiting
NCT07179042Early Phase 1

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Enrolling By Invitation
NCT04510194Phase 3

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

Completed
NCT04114136Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT04264897Phase 3

Antecedent Metabolic Health and Metformin Aging Study

Completed
NCT05768139Phase 1

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Recruiting
NCT07226453Phase 2

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Not Yet Recruiting
NCT06829238Phase 4

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

Recruiting
NCT07541456Phase 4

Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes

Completed
NCT03054519Phase 3

Improve PAD PERformance With METformin

Completed

Drug Details

Intervention Type
DRUG
Total Trials
1,289